Unlike the Get Better campaign — which was built throughout last year — Seeking launched with a full body of creative work, ...

Eli Lilly recently announced the impressive results of its SURMOUNT-5 trial, highlighting Zepbound's efficacy over Wegovy in weight management. This promising development was disclosed alongside ...

President Donald Trump vowed to impose tariffs on pharmaceuticals within two weeks. Eli Lilly, a leader in the industry, could be harmed by the move, but it is already preparing for it.

May 7, 2025 US judge sides with FDA's removal of Lilly's weight loss drug from shortage list A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s ...

Eli Lilly said its Zepbound obesity drug helped patients reduce their waist size by an extra two inches compared to those on Novo Nordisk’s Wegovy in a head-to-head study of the two drugs.

Eli Lilly (NYSE:LLY) on Sunday said that its drug Zepbound (tirzepatide) showed superior weight loss over Novo Nordisk's (NVO) Wegovy (semaglutide) in a Phase 3b head-to-head trial. The detailed ...

That could be bad news for leaders in this sector, including Eli Lilly (NYSE: LLY), the largest pharmaceutical company in the world by market cap. Should investors give up on the stock?

(Reuters) -Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as reducing waist circumference, citing data from a head-to-head trial.

Eli Lilly & Co.’s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...